AstraZeneca
AstraZeneca has a deep-rooted heritage in Oncology and a growing portfolio of new medicines with the potential to transform patients’ lives. With a goal of launching six new medicines before 2020 and a broad pipeline of small molecules and biologics, we are committed to advancing Oncology in four main areas – lung, ovarian, breast, & blood cancers – through a focus on four scientific platforms – Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response, and Antibody-Drug Conjugates.